Cellenkos, Inc.
7 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| CK0801 for Treatment of Aplastic Anemia (NCT07499102) | Cellenkos, Inc. | 2026-08-03 |
| CK0802 for Treatment of Steroid Refractory Graft vs. Host Disease (GVHD) (NCT07576699) | Cellenkos, Inc. | 2026-07-01 |
| Regulatory T Cells for Amyotrophic Lateral Sclerosis (NCT05695521) | Cellenkos, Inc. | 2023-04-03 |
| Leading in MPNs Beyond Ruxolitinib in Combo With T-Regs (NCT05423691) | Cellenkos, Inc. | 2022-12-27 |
| A Clinical Trial of CK0801 (a New Drug) In Patients With Treatment-Resistant Guillain-Barré Syndrome (GBS) (NCT03773328) | Cellenkos, Inc. | 2022-11-01 |
| REgulatory T Cell infuSion fOr Lung Injury Due to COVID-19 PnEumonia (NCT04468971) | Cellenkos, Inc. | 2020-09-29 |
| A Clinical Trial of CK0801 (a New Drug) in Patients With Bone Marrow Failure Syndrome (BMF) (NCT03773393) | Cellenkos, Inc. | 2019-05-30 |
Track Cellenkos, Inc. automatically
Every clearance here is in the API, with alerts when new ones post.